How did the COVID-19 pandemic impact Abbott's financial performance in Q3 2020?

The COVID-19 pandemic significantly boosted Abbott's Diagnostics segment due to the launch and widespread adoption of its COVID-19 testing products, including molecular, antibody, and antigen tests. While this drove overall sales growth, the pandemic also negatively impacted the Medical Devices segment, particularly in areas like cardiovascular and neuromodulation, due to reduced procedure volumes. The company also saw some impact on its pharmaceutical and nutritional businesses in certain markets.

What were the main drivers of sales growth in the third quarter?

The primary driver of sales growth was the Diagnostics segment, largely fueled by the rapid development and commercialization of Abbott's COVID-19 diagnostic tests. Increased demand for these tests on various platforms, including ID NOW, BinaxNOW, and its laboratory-based systems, contributed substantially to the segment's strong performance. Additionally, the Nutritional Products segment showed positive growth, and the Medical Devices segment saw contributions from Diabetes Care.

How is Abbott managing its financial position and liquidity in light of the pandemic?

Abbott maintained a strong financial position, with cash and cash equivalents increasing to $4.48 billion as of September 30, 2020. The company generated substantial cash flow from operations, which helped fund its activities, including debt repayment and dividend payments. Abbott also has access to a $5 billion credit line, providing further liquidity if needed. The company has also been actively managing its debt, including issuing new notes and repaying maturing debt.

What is the outlook for the Established Pharmaceutical Products segment?

The Established Pharmaceutical Products segment experienced a sales decrease in the third quarter of 2020, impacted by market dynamics in key emerging markets and the broader effects of the COVID-19 pandemic. While specific growth drivers like China and other Asian/Latin American countries showed some resilience, overall demand was affected. Future performance will likely depend on the recovery of emerging markets and the company's ability to navigate ongoing market challenges.

ABT 10-Q Quarterly Report Q3 FY2020 — Revenue, Net Income, EPS

Summary

Abbott Laboratories reported strong third-quarter 2020 results, driven significantly by its Diagnostics segment, which benefited from the company's rapid and broad rollout of COVID-19 testing solutions. Total sales increased by 9.6% to $8.85 billion, or 10.6% excluding foreign exchange, with the Diagnostics segment showing a substantial 38.2% increase. This growth in diagnostics, particularly from molecular and rapid tests, helped offset some of the pandemic-related slowdowns in the Medical Devices segment. The company maintained a robust financial position with increased cash reserves and managed its debt effectively.

Financial Highlights

51 data points

Beta

Revenue

$8.85B

0.6% Gross Margin

Net Income

$1.23B

0.1% Net Margin

EPS (Diluted)

$0.69

Total Assets

$69.04B

Cash & Equivalents

$4.48B

Free Cash Flow

$1.57B

Financial Statements

Beta

Revenue	$8.85B
Cost of Revenue	$3.97B
Gross Profit	$4.89B
R&D Expenses	$580.00M
SG&A Expenses	$2.30B
Operating Expenses	$7.36B
Operating Income	$1.50B
Interest Expense	$137.00M
Net Income	$1.23B
EPS (Basic)	$0.69
EPS (Diluted)	$0.69
Shares Outstanding (Basic)	1.77B
Shares Outstanding (Diluted)	1.79B

Key Highlights

1Total net sales increased by 9.6% to $8.85 billion in Q3 2020, with a 10.6% increase excluding foreign exchange.
2The Diagnostics segment saw significant growth of 38.2% (4.1% excluding foreign exchange) due to strong demand for COVID-19 diagnostic tests.
3Medical Devices segment sales grew 3.4% (2.6% excluding foreign exchange), with Diabetes Care showing strong double-digit growth, though other areas experienced COVID-19 related procedure volume declines.
4Established Pharmaceutical Products sales decreased by 9.3% (6.0% excluding foreign exchange), impacted by market dynamics in emerging markets and COVID-19.
5Nutritional Products segment sales increased by 2.6% (4.1% excluding foreign exchange), driven by both pediatric and adult nutritionals.
6Net earnings increased to $1.23 billion ($0.69 per diluted share) in Q3 2020, compared to $960 million ($0.53 per diluted share) in Q3 2019.
7The company's cash and cash equivalents increased to $4.48 billion as of September 30, 2020, up from $3.86 billion at the end of 2019, reflecting strong operating cash flow.

ABBOTT LABORATORIES Quarterly Report for Q3 Ended Sep 30, 2020

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions